-
-
-
-
-
-
-
Jones Trading Reiterates Buy Rating on Capricor Therapeutics (CAPR)
-
-
-
-
-
-
-
Capricor Therapeutics (CAPR) PT Lowered to $22 at Oppenheimer
-
-
-
-
-
-
-
Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program
-
-
-
-
-
-
-
Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

